Search Results - Keith Johnson

Plasma Phosphorylated Tau181 as a Biomarker for Alzheimer's Disease Co‐Pathology in Lewy Body Disease by Rong Ye, Pia Kivisäkk, Anna Goodheart, Hadia Fatima, Erin Peterec, Emma Thibault, Michael Properzi, Keith Johnson, Steven Arnold, Stephen N. Gomperts

Get full text

Long‐term safety and efficacy of lecanemab in early Alzheimer's disease: Results from the clarity AD open‐label extension study by Christopher H. van Dyck, Reisa Sperling, Keith Johnson, Shobha Dhadda, Michio Kanekiyo, David Li, Michelle Gee, Steven Hersch, Michael Irizarry, Lynn Kramer

Get full text

Considerations in the clinical use of amyloid PET and CSF biomarkers for Alzheimer's disease by Antoine Leuzy, Ariane Bollack, Daniela Pellegrino, Charlotte E. Teunissen, Renaud La Joie, Gil D. Rabinovici, Nicolai Franzmeier, Keith Johnson, Frederik Barkhof, Leslie M. Shaw, Alexander Arkhipenko, Suzanne E. Schindler, Lawrence S. Honig, Alexis Moscoso Rial, Michael Schöll, Henrik Zetterberg, Kaj Blennow, Oskar Hansson, Gill Farrar

Get full text

Racial and ethnic differences in plasma biomarker eligibility for a preclinical Alzheimer's disease trial by Doris Patricia Molina‐Henry, Rema Raman, Andy Liu, Oliver Langford, Keith Johnson, Leona K. Shum, Crystal M. Glover, Shobha Dhadda, Michael Irizarry, Gustavo Jimenez‐Maggiora, Joel B. Braunstein, Kevin Yarasheski, Venky Venkatesh, Tim West, Philip B. Verghese, Robert A. Rissman, Paul Aisen, Joshua D. Grill, Reisa A. Sperling

Get full text